Cagrilintide + Semaglutide (5 mg + 5 mg)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency is once weekly by sub-Q injection, held on the same day each week through the full 16 week titration and into maintenance. At 5 mg/mL of total blend, 1 unit on a U-100 syringe is 0.01 mL and carries 50 mcg of blend, which is 25 mcg of cagrilintide plus 25 mcg of semaglutide; every figure in the table above is read off that one conversion. The top maintenance dose of 2.4 mg per peptide is 96 units, or 0.96 mL, so no dose in this protocol exceeds a single U-100 syringe and nothing has to be split into two injections. Technique follows standard sub-Q practice: clean the vial stopper and the skin with alcohol and let both air dry, pinch a skinfold, insert at 45 to 90 degrees, do not aspirate, and inject slowly and steadily. Sites are rotated systematically across abdomen, thighs, and upper arms each week to avoid lipohypertrophy, and a draw approaching 1 mL is delivered over several seconds rather than pushed fast. Each step is held 4 weeks before moving up, which is the single practice that keeps gastrointestinal effects manageable during the climb.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 4: 250 mcg of each peptide weekly at 10 units, an introduction step where gastrointestinal effects are most likely to appear first.
• Weeks 5 to 8: 500 mcg of each weekly at 20 units, with appetite suppression becoming consistent.
• Weeks 9 to 12: 1,000 mcg of each weekly at 40 units, the point where the combination pulls ahead of semaglutide alone in the trial data.
• Weeks 13 to 16: 1,700 mcg of each weekly at 68 units, the last titration rung before the trial target dose.
• Week 17 onward: 2,400 mcg of each weekly at 96 units as maintenance, matching the dose used in the co administered clinical trials.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 30 days. At 5 mg/mL, 1 unit = 0.01 mL » 50 mcg of total blend on a U-100 insulin syringe, which is 25 mcg of cagrilintide plus 25 mcg of semaglutide.
5. Reconstitution math: 5 mg cagrilintide plus 5 mg semaglutide is 10 mg of total blend, and 10 mg divided by 2.0 mL is 5 mg/mL total, or 2.5 mg/mL of each peptide. Step conversions: 250 mcg each = 10 units; 500 mcg each = 20 units; 1,000 mcg each = 40 units; 1,700 mcg each = 68 units; 2,400 mcg each = 96 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C (minus 4 °F) in dry, dark conditions; stable for 12 months or longer.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F), use within 30 days, and avoid freeze thaw cycles.

• Allow vials to reach room temperature before opening, which reduces condensation uptake.
• Keep reconstituted vials out of the refrigerator door where temperature swings are largest, and label each one with the date and the concentration so draw volumes are never guessed.

Supplies Needed

Planning math is based on a 16 week titration running from 500 mcg of total blend in week 1 up to 3,400 mcg of total blend in week 16, at one injection per week.

Peptide Vials (Cagrilintide + Semaglutide, 5 mg + 5 mg):

• The full 16 week titration consumes about 27.6 mg of total blend, which is 3 vials at 10 mg each. A shorter 8 week run consumes about 6 mg, or 1 vial, and a 12 week run consumes about 14 mg, or 2 vials. Maintenance at 2.4 mg of each peptide weekly runs 4.8 mg of blend per week, about 2 vials per month.

Insulin Syringes (U-100):

• Per week: 1 U-100 insulin syringe, since the protocol is a single weekly injection and no dose exceeds 100 units at this concentration.
• Full cycle: 16 syringes across 16 weeks, or 8 and 12 for the shorter runs.

Bacteriostatic Water (10 mL bottles):

• Each 10 mg blend vial takes 2.0 mL, so one 10 mL bottle covers 5 vials, and a single bottle covers the whole 16 week titration with volume to spare.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the skin.
• Full cycle: 32 swabs across 16 weeks, which one 100 count box covers several times over.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for every draw and dispose of them in a sharps container; rotate injection sites across abdomen, thighs, and upper arms each week to reduce local irritation.
• The vial is a fixed blend, so the two peptides cannot be titrated independently. Every draw delivers equal amounts of each: a 40 unit draw is 1,000 mcg of cagrilintide plus 1,000 mcg of semaglutide.
• Higher doses raise the odds of gastrointestinal effects such as nausea and sharply reduced appetite, so each step is held 4 weeks and the weekly dose and injection site are documented to keep the climb consistent.
• A reconstituted vial is used within 30 days, and the early low dose weeks draw only 10 to 20 units per week, so a vial opened in week 1 will reach the end of its window with volume still in it. The 3 vial figure covers the total milligrams; plan for some remainder discarded at the end of an in use window rather than for perfect volume efficiency.
• Injection site reactions reported in the clinical literature are mild and transient; persistent redness, swelling, or pain at a site is a reason to stop and reassess rather than to continue rotating through it.
• Regulatory Note: semaglutide is an approved drug product as a single agent, but cagrilintide is not approved and the co administered cagrilintide plus semaglutide combination remains investigational. Blend vials of this kind are research grade, not pharmaceutical grade, and are labeled for research use only and not for human consumption. WADA status is not addressed in the source material.

How This Works

Cagrilintide is a long acting amylin analog that reduces appetite through central satiety pathways, while semaglutide activates GLP-1 receptors to enhance glucose dependent insulin secretion and suppress glucagon. The combination leverages complementary mechanisms: amylin primarily delays gastric emptying and signals satiety through the area postrema, while GLP-1 enhances pancreatic beta cell function and suppresses appetite centrally. Because the two arms act on different receptor systems that converge on the same hindbrain satiety circuitry, the signals add rather than overlap, and clinical trials of the co administered regimen, CagriSema, show greater body weight reduction than either agent produces alone.

Benefits & Side Effects

Observations from the published record.

• Weight reduction: phase 2 trials report mean body weight loss of about 15 to 17% at 32 weeks with the combination, exceeding semaglutide monotherapy.
• Additive effect: the co administered regimen outperforms either cagrilintide or semaglutide used alone, which is the entire argument for the blend over a single agent.
• Glycemic control: in type 2 diabetes, HbA1c reductions were observed alongside the weight loss.
• Gastrointestinal tolerability: nausea, vomiting, and diarrhea are the most common adverse events; gradual titration minimizes their severity.
• Injection site reactions: mild and transient in clinical reports.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein forward diet tailored to individual energy needs, since appetite suppression at these doses makes it easy to undershoot protein without planning.
• Combine resistance training with aerobic activity to reinforce metabolic adaptations and protect lean mass during a deficit.
• Prioritize sleep and stress management, both of which support adherence through the titration period and recovery from training.
• Stay hydrated and eat slowly in smaller portions to reduce gastrointestinal discomfort, which tracks closely with meal size once gastric emptying slows.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. For volumes exceeding 1 mL (e.g., 1.44 mL at maintenance dose), inject slowly over several seconds.

References

Source citations for further reading.

1. Efficacy and safety of coadministered once weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in T2D: phase 2 trial (Lancet Diabetes Endocrinol, 2024).
2. Safety, tolerability, PK/PD of concomitant cagrilintide with semaglutide 2.4 mg: phase 1b trial (Lancet, 2021).
3. Once weekly cagrilintide for weight management: phase 2 trial in overweight/obesity (Lancet, 2021).
4. Efficacy and safety of CagriSema 2.4 mg plus 2.4 mg in T2D (ScienceDirect, 2024).